Sun Pharma lines up USD 100 mn to commercialise niche products this fiscal

Sun Pharmaceutical Industries has lined up a USD 100 million investment to commercialise innovative products in the current fiscal, according to Chairman and Managing Director Dilip Shanghvi.
ADVERTISEMENT The Mumbai-based drug major said the capital outlay will help in significantly strengthening the company's speciality (patented products) business for the future.
"For the current year, we are looking to invest approximately USD 100 million additionally on the commercialisation of new speciality products," Shanghvi told analysts in a call.
The drug major plans to majorly invest in the launch of two products -- Unloxcyt and Leqselvi.
Unloxcyt is indicated for the treatment of adults with metastatic cutaneous squamous cell carcinoma, while Leqselvi is for the treatment of adults with severe alopecia areata. In FY25, the company's global speciality sales rose 17.1 per cent to USD 1,216 million.
ADVERTISEMENT In the January-March quarter of FY25, the sales were up 8.6 per cent to USD 295 million.Elaborating on the speciality product segment, Shanghvi said it is now seeking a partner for the future development and commercialisation of MM-II (for osteoarthritis pain) in certain geographies.
ADVERTISEMENT "This change is due to the strategic reassessment of our pipeline. We continue to believe in the potential of the product. Another change is that we are now planning a trial of GL0034 in type 2 diabetes as its first indication," he added.
Sun Pharma has agreed to acquire Checkpoint Therapeutics, a company specialising in immunotherapy and targeted oncology, he noted.
ADVERTISEMENT "We are awaiting approval of that transaction and subsequent closing. Checkpoint has recently received approval from USFDA for Unloxcyt for metastatic or locally advanced cutaneous squamous cell carcinoma and we look forward to leveraging our presence to accelerate patient's access to Unloxcyt," Shangvi said.The drug maker expects mid-to-high single-digit consolidated topline growth in the ongoing fiscal.
ADVERTISEMENT Sun Pharma reported a total sales of Rs 5,20,41 crore in FY25.
"On the guidance of FY26, we expect mid-to-high single-digit consolidated topline growth for FY26," Shanghvi said.
The drug firm expects its FY26 R&D spend to be 6-8 per cent of sales for the next year, he added.
(You can now subscribe to our Economic Times WhatsApp channel)

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

Business Standard

25 minutes ago

• Business Standard

Influx Healthtech IPO booked 200x; check allotment, GMP, listing date

Influx Healthtech IPO allotment status: The basis of allotment of shares for Influx Healthtech is expected to be finalised today, Monday, June 23, 2025. The initial public offering (IPO) of Influx Healthtech, which closed for subscription on Friday, June 20, received a robust response from investors, with the offering being over subscribed by over 201 times. Investors bid for 817.53 million equity shares, which was 201.4 times the public issue size of 4.05 million shares, through 220,338 applications. After the allotment process is completed, investors can verify their IPO allotment status by visiting the official websites of the National Stock Exchange (NSE) and Maashitla Securities, the designated registrar for the Influx Healthtech IPO. Alternatively, they can use the direct links provided below to check their allotment status online: Check Influx Healthtech IPO allotment status on NSE: Check Influx Healthtech IPO allotment status on Maashitla Securities: Influx Healthtech IPO grey market premium (GMP) The unlisted shares of Influx Healthtech were trading at ₹118 in the grey market, commanding a premium of ₹22 or 22.3 per cent compared to the upper price band of ₹96 per share, according to sources tracking unofficial markets. Influx Healthtech IPO details The Mumbai-based company aims to raise ₹58.57 crore through a combination of a fresh issue of 5 million equity shares and an offer for sale (OFS) of 1.1 million equity shares at a price band of ₹91-96 per share. Shares of Influx Healthtech are scheduled to be listed on the NSE SME platform on Wednesday, June 25. Rarever Financial Advisors is the sole book-running lead manager. According to the red herring prospectus (RHP), the company intends to use the net fresh issue proceeds for the set up of the manufacturing facility Nutraceutical Division, a manufacturing facility for the Veterinary Food Division; purchase of machinery for Homecare and Cosmetic Division, and general corporate purposes. About Influx Healthtech Incorporated in 2020, Mumbai-based Influx Healthtech is a healthcare-focused company specialising in contract manufacturing. It operates a manufacturing facility located in Thane, Maharashtra. The company produces Dietary and Nutritional Supplements, Cosmetics, Ayurvedic/Herbal Products, Veterinary Feed Supplements, care products, Active Pharmaceutical Ingredients (APIs), and finished dosage forms, including tablets, capsules, and injectables.

Business Standard

39 minutes ago

• Business Standard

India's forex reserves rise to $698.95 Billion

India's forex reserves rose USD 2.294 billion to USD 698.95 billion for the week ended June 13, the RBI said on Friday. For the week ended June 13, foreign currency assets, a major component of the reserves, rose by USD 1.739 billion to USD 589.426 billion, the data released on Friday showed. The gold reserves were up by USD 428 million to USD 86.316 billion during the week, the RBI said. The Special Drawing Rights (SDRs) also rose by USD 85 million to USD 18.756 billion, the central bank said. India's reserve position with the IMF also inched up by USD 43 million at USD 4.452 billion in the reporting week, the apex bank data showed.

Time of India

an hour ago

• Time of India

Sun Pharma Share Price Live Updates: Sun Pharma's Closing Value

23 Jun 2025 | 08:40:17 AM IST Welcome to the Sun Pharma Stock Liveblog, your real-time source for the latest updates and comprehensive analysis on a prominent stock. Dive into the current details of Sun Pharma, including: Last traded price 1665.1, Market capitalization: 399513.27, Volume: 2567882, Price-to-earnings ratio 36.56, Earnings per share 45.55. Our liveblog offers a complete overview of Sun Pharma through a blend of fundamental and technical indicators. Stay informed about breaking news that can shape Sun Pharma's performance in the market. Our market analysis and expert opinions empower you to make informed investment decisions. Join us as we unravel the potential of Sun Pharma in the ever-changing market landscape. The data points are updated as on 08:40:17 AM IST, 23 Jun 2025 Show more